Ascentage Pharma Group International Unsponsored ADR (AAPG) AI Stock Analysis

• Market Cap: $4.26B
• Dividend Yield: N/A
• Average Volume (3M): 8.44K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.27
• Revenue Growth: -56.78%
• EPS Growth: -191.46%
• Country: US
• Employees: 567
• Sector: Healthcare
• Sector Strength: 48
• Industry: Biotechnology
• EPS (TTM): -0.96
• Shares Outstanding: 92,963,370
• 10 Day Avg. Volume: 8,445
• 30 Day Avg. Volume: 8,440
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.79
• Enterprise Value/Revenue: 23.87K
• Enterprise Value/Gross Profit: -9.28K
• Enterprise Value/Ebitda: 4.11K
• 1Y Price Target: $38.00
• Price Target Upside: -20.67% Downside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 43 Neutral
• Price Target: $38.00 ▼(-20.67% Downside)

The most significant factor is the company's financial performance, which shows robust revenue growth but is overshadowed by profitability and cash flow challenges. The technical analysis reflects overbought conditions, and valuation concerns arise from a negative P/E ratio. Together, these factors contribute to a cautious outlook.

Positive Factors

Hospital Inclusion

The number of hospitals with Olver included in their formulary has increased significantly, boosting potential sales.

Revenue Growth

Olver recorded significant revenue growth, surpassing last year's revenue due to NRDL's coverage inclusion.

Negative Factors

Regulatory Application

Lisaftoclax missed the deadline to file for NRDL application, though there is confidence in its strategic opportunities.

Ascentage Pharma Group International Unsponsored ADR Business Overview & Revenue Model

Company Description

Ascentage Pharma Group International Unsponsored ADR (AAPG) is a biopharmaceutical company focused on the discovery and development of innovative therapies for the treatment of cancer, hepatitis B, and age-related diseases. The company operates primarily in the oncology and antiviral sectors, leveraging its proprietary drug development platform to create targeted therapeutics that address unmet medical needs. Ascentage Pharma's core products include novel small molecules designed to inhibit key regulatory proteins involved in tumor growth and viral replication.

How the Company Makes Money

Ascentage Pharma generates revenue through multiple streams, primarily from collaborations and partnerships with other pharmaceutical companies for the development and commercialization of its drug candidates. The company may receive milestone payments and royalties from these collaborations, depending on the success of the drug development process. Additionally, Ascentage Pharma may generate income from grants and research funding aimed at advancing its innovative therapies. Significant partnerships with larger pharmaceutical firms can also provide financial stability and resources necessary for clinical trials and regulatory approvals.

Ascentage Pharma Group International Unsponsored ADR Financial Statement Overview

Summary

The company exhibits strong revenue growth; however, it struggles with profitability and cash flow. High debt levels and negative equity ratios indicate financial risk, necessitating strategic improvements.

Income Statement

The company's revenue has seen significant growth from 2023 to 2024, with a revenue increase of over 340%. However, the company remains unprofitable with a negative net profit margin, and the EBIT and EBITDA margins are also negative, reflecting ongoing operational challenges in achieving profitability.

Balance Sheet

The balance sheet shows a high debt-to-equity ratio, indicating significant leverage which could be risky. The equity ratio is low, suggesting a potential vulnerability to financial instability. The Return on Equity is negative, reflecting ongoing losses.

Cash Flow

While there was a reduction in negative operating cash flow in 2024, the company continues to experience negative free cash flow. The operating cash flow to net income ratio is negative, indicating challenges in translating earnings into cash.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	141.22K	980.65M	221.98M	209.71M	4.33M	12.45M
Gross Profit	-363.27K	951.57M	191.44M	187.71M	24.58M	10.48M
EBITDA	819.47K	-237.63M	-743.61M	-771.47M	-787.19M	-641.77M
Net Income	-2.01M	-405.43M	-925.64M	-882.92M	-782.42M	-677.61M
Balance Sheet
Total Assets	86.56M	2.62B	2.50B	2.83B	2.94B	1.73B
Cash, Cash Equivalents and Short-Term Investments	50.58M	1.24B	1.07B	1.48B	273.61M	1.02B
Total Debt	0.00	1.67B	1.80B	1.79B	1.08B	529.70M
Total Liabilities	116.92M	2.34B	2.43B	2.42B	1.71B	884.42M
Stockholders Equity	-32.61M	264.19M	60.42M	408.66M	1.23B	846.62M
Cash Flow
Free Cash Flow	-9.36M	-135.65M	-782.92M	-890.88M	-1.04B	-861.43M
Operating Cash Flow	-9.06M	-111.36M	-726.08M	-653.91M	-604.68M	-609.96M
Investing Cash Flow	28.12M	-362.04M	21.92M	-384.61M	-466.52M	-107.37M
Financing Cash Flow	0.00	314.77M	368.75M	619.27M	1.78B	1.04B

Ascentage Pharma Group International Unsponsored ADR Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	60 Neutral	HK$19.22B	4.48	-1.43%	3.30%	11.19%	-15.58%
PTGX	60 Neutral	$3.49B	80.66	8.61%	―	-34.45%	-69.75%
KYMR	53 Neutral	$3.05B	―	-33.26%	―	-49.51%	-44.09%
CRNX	52 Neutral	$2.77B	―	-36.94%	―	―	-9.10%
IMVT	45 Neutral	$2.58B	―	-77.58%	―	―	-48.38%
AAPG	43 Neutral	$4.26B	―	-161.90%	―	-56.78%	-191.46%
MLTX	41 Neutral	$3.38B	―	-40.29%	―	―	-208.46%